Clinical Trial Update: Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of camrelizumab and bevacizumab in adults with recurrent glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Beijing Sanbo Brain Hospital | Conditions: Recurrent Glioblastoma | Phase 2 | Status: TERMINATED